Home > Keywords > Thématique > Science

Science

Articles

  • TIDES Asia, March 2-5 2021 - 100% Virtual
    4 March 2021, by Elodie DORMES

    Guillaume JACQUOT PharmD, PhD, will present last company results on extra-hepatic delivery of oligonucleotides.

  • Festival of Biologics 2019 in BASEL
    31 October 2019, by Elodie DORMES

    Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».

  • TIDES Europe, Nov. 11-13, 2020 - 100% Virtual
    12 November 2020, by Elodie DORMES

    Dr Guillaume JACQUOT will share a presentation on “TfR-targeting VHH Nanobodies for Extra-hepatic Delivery of Oligonucleotides” a good opportunity for Vect-Horus to present its last results.
    A live Q&A session will also give the opportunity to ask questions on last trends and highlights in Oligonucleotide & Peptide Therapeutics field to expert panelists.
    TIDE is the Europe’s #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate new (…)

  • Vect-Horus focuses on Target engagement and intracellular delivery of LDLR conjugates to design new targeted drug therapies
    27 November 2019, by Elodie DORMES

    Varini et al. J Control Release 2019
    Targeted delivery to specific tissues and subcellular compartments is of paramount importance to optimize therapeutic or diagnostic interventions while minimizing side-effects. Using recently identified LDL receptor (LDLR) -targeting small synthetic peptide-vectors conjugated to model cargos of different nature and size, we investigated in LDLR-expressing cells the impact of vector-cargo molecular engineering and coupling valency, as well as the (…)

  • Oligonucleotides for CNS Congress from February 22-24, 2021
    2 February 2021, by Elodie DORMES

    Dr Michel KHRESTCHATISKY will join the session dealing with “Exploring Extra-Hepatic Delivery to Relevant Targets within the CNS & Muscle” and give a talk to describe the use of VECT-HORUS “Molecular Vectors for Targeted Delivery of Oligonucleotides”.

  • Early September VECT-HORUS’ team will be attending the EANM2023 Annual Congress!
    8 September 2023, by Emmanuelle BETTENDORF

    On this occasion, our partner Radiomedix, Inc. , was selected to present an update of our joint research program. This talk untitled “Glioblastoma and Pancreatic Adenocarcinoma - Versatile radiolabeled probe targeting Low Density Lipoprotein Receptors (LDLR)” will be given Sunday, September 10th between 4:55 PM and 5:05 PM at the Hall E2 by Izabela Tworowska.
    Come and take the opportunity to meet and discuss with Vect-Horus on September 9-13, 2023 in Vienna!
    Our #Oncology team, Cedric (…)

  • Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
    28 January 2019, by Jonathan NOWAK

    (Molino et al., 2017, The FASEB Journal)
    www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)

  • Blood Brain Barrier Summit delivered digitally
    10 August 2020, by Elodie DORMES

    Vect-Horus will assist to the Blood Brain Barrier Summit, delivered digitally from August 31 to September 2nd, 2020

  • Vect-Horus team will attend the 8AIS2020 symposium from Nov. 23-26, 2020
    12 November 2020, by Elodie DORMES

    Marion DAVID will be presenting a poster entitled “Development of versatile single domain antibody vectors that enhance brain deliver of antibodies by targeting the TfR transport system. ”
    Please use the partnering system to contact us and organize a 1&1 meeting : www.aiscongress.com